Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacytidine plus low-dose venetoclax for relapsed or refractory elderly acute myeloid leukemia
ChiCTR2100050627Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Oct 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of azacitidine and venetoclax in acute myeloid leukemia (AML), sponsored by Beijing Hospital. Primary endpoints: Complete remission rate, Complete remission with incomplete blood count recovery and 5 more. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
azacitidinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2100050627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050627.